Finding 1078623 (2020-003)

Material Weakness Repeat Finding
Requirement
P
Questioned Costs
$1
Year
2020
Accepted
2024-10-10

AI Summary

  • Core Issue: Inaccurate reconciliation of federal grant accounts led to overdrawn balances, creating a liability to the federal government.
  • Impacted Requirements: Noncompliance with 2 CFR 200.508 and 2 CFR 200.510 regarding financial statements and management of federal awards.
  • Recommended Follow-Up: Ensure schedules for financial entries are prepared and reviewed by supervisors; train staff and complete reconciliations by October 15, 2024.

Finding Text

Finding 2020-003: Reconciliation of Accounts Federal Program: Research and Development Cluster (Education and Human Resources) Assistance Listing Number and Title: 47.076 STEM Education Name of Federal Agency, Pass Through Entity (when applicable), Award Number and Year: National Science Foundation: 1812860 (9/1/2018 – 8/31/2020), 1940925 (1/15/2020 – 12/31/2023) Material Weakness in Internal Control over Compliance, Material Noncompliance Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation): According to 2 CFR 200.508 "Auditee Responsibilities" the auditee must prepare appropriate financial statements, including the SEFA (as specifically defined under 2 CFR 200.510 "Financial statements"). Title 2 CFR 200.510 "financial statements" requires recipients of Federal funds to prepare a SEFA for the period covered by the auditee's financial statements, which must include the total Federal awards expended. In addition, as noted in 2 CFR 200.302 "Financial management", the financial management system of each non-Federal entity must provide for identification, in its accounts, of all Federal awards received and expended and the Federal programs under which they were received, and records that identify adequately the source and application of funds for federally-funded activities including expenditures. Condition: The year-end schedules for federal grants receivable, for net assets, and for vacation payable were not reconciled and needed to be revised and updated. Cause: Errors in transferring balances between years occurred, which impacted carry-over amounts and the ending balances as of 12/31/2020. Related to vacation payables, the schedule had not been properly adjusted to account for the number of days in the last pay period. Effect or Potential Effect: Three federal grant accounts were overdrawn as of 12/31/2020, creating a liability to the federal government. The related grant receivable and liability balances were not properly stated before adjustment as a result. Questioned Costs: $77,113 in total. Assistance listing number 47.076. Of this amount, $62,403 applies to award ID 1505278, which was closed before 1/1/2020 and did not have expenses or drawdowns in 2020 but by the end of 2018 had $138,034 in federal funding provided to AAPT and $75,631 of reimbursable expenses. AAPT had not refunded the overpayment, such as by applying this $62,403 as a reduction in federal reimbursements drawn during 2020. The remaining amounts of $10,654 and $4,056 relate to award IDs 1812860, and 1940925, respectively, and were calculated in the same manner. The period of performance for award ID 1812860 ended on 8/31/2020. Award ID 1940925 was active through 12/31/2020. Identification as a Repeat Finding, if Applicable: 2019-002 Recommendation: We recommend AAPT staff prepare schedules used to prepare entries into the accounting information system or which the information in the schedules will otherwise be used to initiate financial transactions, and the transactions and schedules be reviewed by a supervisor. Views of Responsible Officials and Planned Corrective Actions: The outstanding liability due to NSF of $73,057 will be reimbursed when AAPT files the next drawn down request. Anticipated date of drawn down will be by April, 30,2024 The remaining balance was earned in 2021. The senior accountant will be trained to prepare entries previously prepared by the CFO The senior accountant will reconcile accounts, and provide updated current schedules. The CFO will review and approve the entries and schedules prepared by the Senior accountant. Anticipated Completion Date: October 15, 2024 Responsible Official: Michael Brosnan, CFO

Categories

Questioned Costs Cash Management Material Weakness Period of Performance Reporting Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 502144 2020-001
    Significant Deficiency
  • 502145 2020-002
    Material Weakness Repeat
  • 502146 2020-005
    Significant Deficiency Repeat
  • 502147 2020-001
    Significant Deficiency
  • 502148 2020-002
    Material Weakness Repeat
  • 502149 2020-005
    Significant Deficiency Repeat
  • 502150 2020-001
    Significant Deficiency
  • 502151 2020-002
    Material Weakness Repeat
  • 502152 2020-004
    Significant Deficiency
  • 502153 2020-005
    Significant Deficiency Repeat
  • 502154 2020-001
    Significant Deficiency
  • 502155 2020-002
    Material Weakness Repeat
  • 502156 2020-004
    Significant Deficiency
  • 502157 2020-005
    Significant Deficiency Repeat
  • 502158 2020-001
    Significant Deficiency
  • 502159 2020-002
    Material Weakness Repeat
  • 502160 2020-005
    Significant Deficiency Repeat
  • 502161 2020-006
    Significant Deficiency Repeat
  • 502162 2020-001
    Significant Deficiency
  • 502163 2020-002
    Material Weakness Repeat
  • 502164 2020-005
    Significant Deficiency Repeat
  • 502165 2020-001
    Significant Deficiency
  • 502166 2020-002
    Material Weakness Repeat
  • 502167 2020-004
    Significant Deficiency
  • 502168 2020-005
    Significant Deficiency Repeat
  • 502169 2020-001
    Significant Deficiency
  • 502170 2020-002
    Material Weakness Repeat
  • 502171 2020-005
    Significant Deficiency Repeat
  • 502172 2020-001
    Significant Deficiency
  • 502173 2020-002
    Material Weakness Repeat
  • 502174 2020-005
    Significant Deficiency Repeat
  • 502175 2020-001
    Significant Deficiency
  • 502176 2020-002
    Material Weakness Repeat
  • 502177 2020-003
    Material Weakness Repeat
  • 502178 2020-005
    Significant Deficiency Repeat
  • 502179 2020-001
    Significant Deficiency
  • 502180 2020-002
    Material Weakness Repeat
  • 502181 2020-003
    Material Weakness Repeat
  • 502182 2020-005
    Significant Deficiency Repeat
  • 502183 2020-001
    Significant Deficiency
  • 502184 2020-002
    Material Weakness Repeat
  • 502185 2020-005
    Significant Deficiency Repeat
  • 502186 2020-001
    Significant Deficiency
  • 502187 2020-002
    Material Weakness Repeat
  • 502188 2020-005
    Significant Deficiency Repeat
  • 502189 2020-001
    Significant Deficiency
  • 502190 2020-002
    Material Weakness Repeat
  • 502191 2020-005
    Significant Deficiency Repeat
  • 502192 2020-001
    Significant Deficiency
  • 502193 2020-002
    Material Weakness Repeat
  • 502194 2020-005
    Significant Deficiency Repeat
  • 502195 2020-001
    Significant Deficiency
  • 502196 2020-002
    Material Weakness Repeat
  • 502197 2020-005
    Significant Deficiency Repeat
  • 502198 2020-001
    Significant Deficiency
  • 502199 2020-002
    Material Weakness Repeat
  • 502200 2020-005
    Significant Deficiency Repeat
  • 502201 2020-001
    Significant Deficiency
  • 502202 2020-002
    Material Weakness Repeat
  • 502203 2020-005
    Significant Deficiency Repeat
  • 1078586 2020-001
    Significant Deficiency
  • 1078587 2020-002
    Material Weakness Repeat
  • 1078588 2020-005
    Significant Deficiency Repeat
  • 1078589 2020-001
    Significant Deficiency
  • 1078590 2020-002
    Material Weakness Repeat
  • 1078591 2020-005
    Significant Deficiency Repeat
  • 1078592 2020-001
    Significant Deficiency
  • 1078593 2020-002
    Material Weakness Repeat
  • 1078594 2020-004
    Significant Deficiency
  • 1078595 2020-005
    Significant Deficiency Repeat
  • 1078596 2020-001
    Significant Deficiency
  • 1078597 2020-002
    Material Weakness Repeat
  • 1078598 2020-004
    Significant Deficiency
  • 1078599 2020-005
    Significant Deficiency Repeat
  • 1078600 2020-001
    Significant Deficiency
  • 1078601 2020-002
    Material Weakness Repeat
  • 1078602 2020-005
    Significant Deficiency Repeat
  • 1078603 2020-006
    Significant Deficiency Repeat
  • 1078604 2020-001
    Significant Deficiency
  • 1078605 2020-002
    Material Weakness Repeat
  • 1078606 2020-005
    Significant Deficiency Repeat
  • 1078607 2020-001
    Significant Deficiency
  • 1078608 2020-002
    Material Weakness Repeat
  • 1078609 2020-004
    Significant Deficiency
  • 1078610 2020-005
    Significant Deficiency Repeat
  • 1078611 2020-001
    Significant Deficiency
  • 1078612 2020-002
    Material Weakness Repeat
  • 1078613 2020-005
    Significant Deficiency Repeat
  • 1078614 2020-001
    Significant Deficiency
  • 1078615 2020-002
    Material Weakness Repeat
  • 1078616 2020-005
    Significant Deficiency Repeat
  • 1078617 2020-001
    Significant Deficiency
  • 1078618 2020-002
    Material Weakness Repeat
  • 1078619 2020-003
    Material Weakness Repeat
  • 1078620 2020-005
    Significant Deficiency Repeat
  • 1078621 2020-001
    Significant Deficiency
  • 1078622 2020-002
    Material Weakness Repeat
  • 1078624 2020-005
    Significant Deficiency Repeat
  • 1078625 2020-001
    Significant Deficiency
  • 1078626 2020-002
    Material Weakness Repeat
  • 1078627 2020-005
    Significant Deficiency Repeat
  • 1078628 2020-001
    Significant Deficiency
  • 1078629 2020-002
    Material Weakness Repeat
  • 1078630 2020-005
    Significant Deficiency Repeat
  • 1078631 2020-001
    Significant Deficiency
  • 1078632 2020-002
    Material Weakness Repeat
  • 1078633 2020-005
    Significant Deficiency Repeat
  • 1078634 2020-001
    Significant Deficiency
  • 1078635 2020-002
    Material Weakness Repeat
  • 1078636 2020-005
    Significant Deficiency Repeat
  • 1078637 2020-001
    Significant Deficiency
  • 1078638 2020-002
    Material Weakness Repeat
  • 1078639 2020-005
    Significant Deficiency Repeat
  • 1078640 2020-001
    Significant Deficiency
  • 1078641 2020-002
    Material Weakness Repeat
  • 1078642 2020-005
    Significant Deficiency Repeat
  • 1078643 2020-001
    Significant Deficiency
  • 1078644 2020-002
    Material Weakness Repeat
  • 1078645 2020-005
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
47.049 Mathematical and Physical Sciences $10,562
47.076 Education and Human Resources $6,442
43.001 Science $4,172